VALN - צמיחת רווח נקי למניה משנה לשנה ב-12 החודשים האחרונים Valneva Pharma

Valneva SE (VALN) benefits from inelastic demand for tourist vaccinations and the uniqueness of its Chikungunya vaccine. The quarterly EPS growth trend captures the market response, where -137.20 serves as the current metric level. However, success depends on the approval of new products, while business resilience relies on streamlined European logistics and strict supply quality control.

For Valneva SE (VALN), quarterly earnings per share (EPS) growth on GURU.Markets reflects the dynamics of net income attributable to a single ordinary share. This metric measures the percentage change of this value relative to the same period last year. This calculation reveals the efficiency of capitalizing on the scientific achievements of the company's elite virologists. A positive trend confirms the successful commercialization of vaccines. It is critical for investors to correlate these fluctuations with market cycle phases.